Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boots in the U.S.

This article was originally published in The Tan Sheet

Executive Summary

Firm will devote an additional $171 mil. (€1=$1.42) to support its three "core" brands - Clearasil, Stepsils medicated lozenges and Nuraphen analgesics - over the next four years. Increased support is part of Boots' effort to boost profit from the $84.9 mil. earned in 2001 to $142.5 mil. by 2005; the additional monies will be split between marketing and new product development, company says. New ads for Clearasil, designed by Grey Global Group, will debut in the U.S. in May and feature a "contemporary" perspective on acne. Four new Clearasil products also are slated to debut stateside later this year, firm notes. Boots acquired Clearasil from P&G in 2000 (1"The Tan Sheet" Oct. 23, 2000, p. 7)...
Advertisement

Related Content

P&G Divests Clearasil, Boots Healthcare Gains Access To U.S. Market
P&G Divests Clearasil, Boots Healthcare Gains Access To U.S. Market

Topics

Advertisement
UsernamePublicRestriction

Register

PS093655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel